Open for Innovation

Forming mutually beneficial alliances with world-class biotech companies to help bring transformative science from target to clinical proof of concept

Watch Video ››

Spotlight on our Collaboration with ChemoCentryx:

GSK Exercises Option to Progress Development of ChemoCentryx's CCR9 Antagonist Traficet-EN for the Treatment of Inflammatory Bowel Diseases

Agility, Imagination, Flexibility

A Spotlight on the ceedd's Biology and Business Specialist: Declan Jones, Ph.D., Research Director

Read Bio ››

At GlaxoSmithKline (GSK) a specialized R&D unit is driving growth in external drug discovery to complement the late-stage GSK pipeline.The Center of Excellence for External Drug Discovery (ceedd) builds and personally manages unique risk/reward-sharing drug discovery alliances with world class biotech companies. We work directly with these companies to bring programs from target to clinical proof of concept, at which stage GSK has options to license for full development and commercialization. As a small, multidisciplinary team, we share our alliance companies’ entrepreneurial spirit and agility, and complement their capabilities with broad expertise and access to big pharma resources to bring innovative new medicines to more patients more quickly.